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Background. The heart-to-mediastinum ratio (HMR) of 123I-metaiodobenzylguanidine
(MIBG) showed variations among institutions and needs to be standardized among various
scinticamera-collimator combinations.
Methods. A total of 225 phantom experiments were performed in 84 institutions to cal-
culate cross-calibration coefficients of HMR. Based on phantom studies, a conversion coefficient
for each camera-collimator system was created, including low-energy (LE, n 5 125) and a
medium-energy (ME, n 5 100) collimators. An average conversion coefficient from the most
common ME group was used to calculate the standard HMR. In clinical MIBG studies (n 5 52)
from three institutions, HMRs were standardized from both LE- and ME-type collimators and
classified into risk groups of <1.60, 1.60-2.19, and ‡2.20.
Results. The average conversion coefficients from the individual camera-collimator con-
dition to the mathematically calculated reference HMR ranged from 0.55 to 0.75 for LE groups
and from 0.83 to 0.95 for ME groups. The conversion coefficient of 0.88 was used to unify
HMRs from all acquisition conditions. Using the standardized HMR, clinical studies (n 5 52)
showed good agreement between LE and ME types regarding three risk groups (j 5 0.83,
P < .0001, complete agreement in 90%, 42% of the patients reclassified into the same risk
group).
Conclusion. By using the reference HMR and conversion coefficients for the system, HMRs
with various conditions can be converted to the standard HMRs in a range of normal to low
HMRs. (J Nucl Cardiol 2014;21:970–8.)
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INTRODUCTION
I-123 metaiodobenzylguanidine (MIBG) has been
used in patients with chronic heart failure, ischemic
heart disease, and cardiomyopathy. The most widely
accepted application, however, is in patients with heart
failure.1,2 More than 20-year experiences in this field has
been accumulated in Japan, and use of MIBG in
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prognostic evaluation is described in Japanese Circula-
tion Society’s Nuclear Cardiology Guidelines.3 The
neurological application of MIBG has also become
common, in particular in patients with Lewy-body
diseases.4,5
In most of the MIBG studies, the quantification
method was essential in differentiating normal and
abnormal sympathetic activity, and also high-risk and
low-risk groups. The heart-to-mediastinum ratio (HMR)
was a simple ratio of the heart and background, and
generally good reproducibility has been reported in a
single center analysis.6,7 When multiple centers are
involved in a study, however, there are some preferences
for the location of regions of interest (ROIs), which
potentially cause variations among institutions and pub-
lished studies. More importantly, HMR based on the
medium-energy (ME) collimator showed higher values
than that based on low-energy (LE) collimators.8 The
nomenclature of collimators is classified into two major
groups of LE and ME, but the camera vendors have
created various types of collimators depending on the
purpose in order to achieve good balance among resolu-
tion, sensitivity, and applicable energy range. The low-
medium energy (LME) collimator is one of the examples
created to cover the higher energy scatter portion of the
123I energy spectrum, in accordance with the widely used
123I-labeled radiopharmaceutical in Japan.
We have already made a phantom for MIBG planar
imaging to cross-calibrate two acquisition conditions.9
As an extension of this idea, the purposes of this study
were to accumulate MIBG data for the HMR from
common vendors, and to establish the cross-calibration
method among various camera and collimator combi-
nations. Our hypothesis in this study is that all camera-
collimator combinations can be unified to a standard
HMR, so that comparison among multiple centers and
the previous studies can be practically performed. The
validity was also tested in clinical studies.
METHODS
Phantom Design
Details of the phantom were written elsewhere.9 In brief
terms, since the purpose of this phantom was to standardize the
HMR among different collimator types by minimizing effects
of septal penetration and Compton scatter, we tried to simplify
the structure as much as possible, in order to calculate the same
HMR using planar images (Taisei Medical, Co. Ltd, Osaka,
Japan; Hokuriku Yuuki, Co. Ltd, Kanazawa, Japan). Each
organ part, namely, heart, mediastinum, lung, and liver, was
designed so that the radioactivity was distributed uniformly in
the organ regions. The size of the phantom was 380 mm in
width and length, and each organ was flat with a constant
concentration. The thickness of each organ was adjusted by
changing the number of acrylic slices. The acrylic slices, 5 mm
in thickness, were pasted with various numbers and orders. The
upper and lower slices were 10 mm in thickness. Four HMRs
from anterior and posterior views were obtained from two
types of the phantom.
A Phantom Experiment
123I-MIBG of 111 MBq in 4,450 mL was prepared and
filled into the two phantoms. Since all organ parts were
connected as one compartment, no adjustment of radionuclide
concentration for each organ part was required. A 3-cm acrylic
plate was placed over the phantom when imaging was
performed. The 256 matrix images were acquired from the
anterior and posterior views for 3-10 minutes, which was a
situation comparable to clinical MIBG imaging. The energy
was centered at 159 keV with a 20% window. Hospitals using
a 15% window also measured HMRs with this condition. The
experiments were performed using 225 conditions in 84
institutions (see ‘‘Appendix’’).
A Mathematical Reference Value of HMRs
HMRs were mathematically calculated in these models,
assuming the linear attenuation coefficient (l) of 123I for water
as 0.147 cm-1. The standard equation for attenuation, that is
exponential of (-lx), where x was thickness of attenuation,
was used. For calculation purpose, slices were divided into
0.05 mm slices, and the summation of the count was calculated
using Mathematica software (version 9, Wolfram Research,
Inc., Champaign, IL). The mathematical reference HMR was
the attenuation corrected HMR, while Compton scatter and
septal penetration of gamma rays were not included. The
reference HMR was 3.50 and 2.60 for the type 1 phantom, and
1.80 and 1.55 for the type 2 phantoms.9
Cross Calibrations
A calibration method from LE-type collimator to ME-
type collimator comparable values was already described.10 In
this study, 4 or 2 HMRs from 2 phantoms types (anterior and
posterior views for each) were plotted to the reference values
(Figure 1). A linear regression equation was calculated using
the formula of y - 1 = K * (x - 1) (* denotes multiplica-
tion), in which the line always passes on the coordinate (1,1).
The first step was to convert the HMR with LE-collimator to
the reference value (HMRref) using coefficient Ka, which is the
slope of the regression line in condition A. The second step
was to convert from the HMRref to a standardized HMR
(HMRstandard) using the Kstandard. The Kstandard was defined as
average K values for typical ME collimators. The conversion
coefficient of HMR from LE to the standardized condition was
identical to Kstandard/Ka. The rationale for this conversion to the
common ME-type is based on practical consideration, so that
most of the users of the ME-collimator can use their routine
HMRs.
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Clinical MIBG Imaging
Anterior MIBG images were obtained with a 256 9 256
matrix format for 3-5 minutes. In Hospital A, Prism 2000 with
a LEHR collimator (Picker, Co. Ltd., Tokyo, Japan) and
E.CAM Signature with LMEGP collimators (Siemens Japan
Co. Ltd., Tokyo) were used (n = 12). In Hospitals B, GCA-
9300A three-detector gamma cameras with LEHR (Toshiba,
Tochigi, Japan) and LMEGP collimators (Siemens Japan Co.
Ltd., Tokyo, Japan) were used (n = 10). In Hospital C,
E.CAM systems with LEHR and LMEGP (Toshiba, Tochigi,
Japan) were used (n = 15). In the Hospitals A and B,
acquisition energy was set 159 keV with a 20% window, and
with a 15% window in Hospital C according to institutional
routine conditions. We did not change their preference for
routine acquisition conditions. In Hospitals A and B, only a
delayed image at 3 hours was obtained with two LE and ME
conditions, and in Hospital C both 20-minute (early) and 3-
hour (delayed) images were obtained. Thus, a total of 52
studies were obtained by both LE- and ME-type conditions in
37 patients (16 males and 21 females, aged 71 ± 10 years).
Indication of the MIBG study was not specified in this
technological validation study. However, the indications
included ischemic and non-ischemic cardiac diseases suspi-
cious of having heart failure and neurological diseases as
Parkinson disease or syndrome, Alzheimer disease, and
dementia with Lewy bodies.
HMRs were calculated using a semiautomatic ROI setting
software.11 In the software algorithm, the heart region was set
as a circle after manually pointing to the center of the heart,
and a rectangular region was determined in the upper medi-
astinum, in which the width was 10% of the body, and the
height was the upper 30% of the mediastinum. All the data
were anonymized and processed in each hospital, and the
calculated data were sent to Kanazawa University. Informed
consent was obtained from all patients in each hospital. Ethical
committees or comparable institutional regulation approved
the study.
Statistics
The data are shown as mean ± standard deviation. A
difference among groups was examined by one-way analysis
of variance and Student’s t test. The linear regression equation
of the HMRs between two conditions was calculated by the
least square method. When the HMRs were classified into
three risk groups, considering that the average HMR in the
normal databases was 2.8 and the lower limit was 2.2,
thresholds of C2.20 (normal range or higher) and 1.60-2.19
(low risk) and \1.60 (high risk) were used. These thresholds
were generally in agreement with the risk classifications used
in heart failure patients.1-3,12,13 Contingency table analysis was
performed and degree of agreement was tested. P values\0.05
were considered significant. The statistics software JMP
version 10 (SAS Institute Inc., Cary, NC, USA) was used,
and mathematical calculation was based on Mathematica 9
(Wolfram Research Inc., Champaign, IL, USA).
RESULTS
Number of Experiments and Participating
Institutions
A total of 225 experiments were performed in 84
institutions, including 7 camera vendors of Siemens
(n = 71), GE (n = 56), Toshiba (n = 50), Shimadzu
(n = 23), Philips (n = 19), Hitachi/Philips (n = 5), and
ADAC (n = 1). Collimator types were divided into two
major groups of LE (n = 125) and ME (n = 100). The LE
groups included high-resolution (LEHR), general-pur-
pose (LEGP), all-purpose (LEAP), general-all-purpose
(LEGAP), extended LE general-purpose (ELEGP), and
cardiac high-resolution (CHR). The ME group included
low-medium-energy general-purpose (LMEGP), general-
purpose (MEGP), general-all-purpose (MEGAP), low
Figure 1. Conversion of HMR from the condition A (HMRa) to the reference value (HMRref), and
to the standard value (HMRstandard). In this study, Kstandard of 0.88 is used as the conversion
coefficient, which is an average coefficient of common ME collimators. Asterisk denotes
multiplication.
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penetration (MELP), and high-energy general-purpose
(HEGP). The nomenclature of collimators depended on
manufacturers’ specifications.
HMRs Measured in Four Phantom
Conditions
When HMRs were obtained using four phantom
conditions, the LE-collimator group showed lower
values compared with the ME-collimator group. For
the phantom of HMR 1.55, LE-collimator (n = 125) and
ME-collimator (n = 100) groups showed 1.40 ± 0.06
and 1.51 ± 0.06 (P \ .0001). Similarly, the phantoms of
HMR 1.80, 2.60, and 3.50 showed 1.53 ± 0.07 and
1.69 ± 0.07 (P \ .0001), 2.00 ± 0.13 and 2.45 ± 0.12
(P \ .0001), and 2.43 ± 0.19 and 3.10 ± 0.17
(P \ .0001), for LE and ME groups, respectively.
Distribution of the mathematical HMR of 1.8, 2.6 is
shown as examples (Figure 2). While both LE and ME
groups differed significantly, overlap of histogram
distributions was also observed.
Conversion Coefficients Determined by 4
and 2 Data Points
When cross-calibration equations passing on the (x,
y) coordinate of (1,1) were made based on all 4 points and
higher 2 points, the distribution of coefficients showed
high correlation between two methods: (slope from the 2
points) = -0.0197 ? 1.027 9 (slope from the 4 points)
(R2 = 0.997, P \ .0001). We therefore used coefficients
from the upper two points in the following analyses.
The conversion coefficients to the reference value
are summarized according to the main collimator names,
namely 5 LE subgroups and 3 ME subgroups (Table 1).
Since the ELEGP collimator showed two separate
distributions between old (2002-2004) and new (2008-
2013) types due to modification of specification, it was
divided into two subgroups. The average conversion
coefficients were 0.55 for LEHR, 0.65 for LEGP/AP,
0.83 for LMEGP, and 0.88 for MEGP, and the highest
was 0.95 for MELP/HEGP types. The difference among
subgroups was highly significant (F ratio 214,
P \ .0001). When the conversion coefficient was divi-
ded into two groups, the average values were
0.595 ± 0.078 for the LE group and 0.865 ± 0.067 for
the ME groups (F ratio 750, P \ .0001) (Figure 3).
HMRs from LE and ME Collimators and
Effect of Standardization
As shown in Figure 4B, D, HMRs from LE-colli-
mator types were corrected using an experimentally
determined conversion coefficient to the reference value
based on the results of individual hospitals. It was
converted again from the reference value to HMRstandard
using a coefficient of Kstandard = 0.88, which derived
from the average coefficient of the MEGP collimator
(Table 1). HMRs from ME-collimator types were
similarly converted to the HMRstandard using
Kstandard = 0.88.
HMRs with the LE-collimator group showed sig-
nificant underestimation; (HMR with LE-
collimator) = 0.62 ? 0.47 9 (HMR with ME-collima-
tor) (Figure 4A). After the correction to standardized
HMRs for both LE and ME collimators, they showed
comparable values below 2.5. However, underestimation
of approximately 10% was observed in an HMR range of
[2.5. The relationship below HMR \2.8 with ME-
collimator is plotted in Figure 4C, D.
When the HMR was divided into three groups using
the threshold of 2.2 and 1.6, the contingency table
showed that the degree of agreement was j 0.07 (95%
confidence of interval [CI] -0.026 to 0.17, P = .21) and
complete agreement was 25/52 (48%) between the
HMRs from LE and ME types (Table 2). However, the
standardized HMR to the average ME-type showed good
agreement between the corrected LE-type and corrected
ME types (j 0.83, 95% CI 0.69-0.97, P \ .0001) and
complete agreement was 47/52 = 90%. A total of 22
patients (42%) were reclassified into the same risk
groups after standardization.
Figure 2. Distribution histograms of HMRs using phantoms
with the reference HMR of 1.80 (a) and 2.60 (b). While the
ME group shows higher values than the LE group, overlaps are
observed.
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DISCUSSION
As a number of MIBG studies have been performed
using the HMR in fields of cardiology and neurology,
this study focused on unifying the methods for calcu-
lating HMR. Using the calibration phantom experiments
and measured conversion coefficients specific for indi-
vidual camera-collimator systems, all the HMRs could
be converted to standardized HMRs using the average
conversion coefficient of the commonest ME types. The
standardized HMRs were applicable to multiple institu-
tions in the range of normal to low HMR values.
The difference in collimator types is one of the most
important factors that affect the variation of HMRs. In
particular, HMRs derived from ME-type collimators are
significantly higher than those from LE-type collima-
tors.9,14,15 As shown in the JSNM-working group normal
databases of 123I-MIBG, average late HMR was 2.5 and
3.0 for LE-collimator and ME-collimator groups.16 The
EANM Cardiovascular Committee and the European
Council of Nuclear Cardiology recommended the use of
the ME-collimator, which provided stable results.8
However, the classification into two collimator types
seems to be too simple today. Collimator specifications
have been modified to cover a higher energy of 159 keV
of 123I, and the LME collimator, which is widely used in
Japan, and extended low-energy collimators have
become available. Even in ME types, the effects of
septal penetration and Compton scatter depend on the
three-dimensional structure of the collimator septa and
holes. Therefore, a correction method to integrate a large
variation of collimator design was sought after.
Regarding acquisition conditions, both energy win-
dows of 20% and 15% have been used and acquisition
time ranged from 3 to 10 minutes in Japan. However, in
this study, although we decided on common data
acquisition protocol in the phantom study, we did not
compel all hospitals to use specific acquisition condi-
tions for clinical MIBG imaging. A minor difference in
conversion coefficients might have therefore been
observed even with the same collimator due to acqui-
sition conditions. Even with a single vendor’s camera
and collimator combination, an SD of coefficient was
0.02-0.03 as shown in Table 1. The reasons for this
variation might be explained by composite factors such
as an energy window (15% or 20%), acquisition time,
and back scatter from the opposite detector, SPECT
couch and floor. Although fraction of the high-energy
Table 1. Conversion coefficients to mathematical reference values
Collimator LE or ME N Mean SD Lower 95% Upper 95% Vendor and number
LEHR LE 73 0.55 0.05 0.54 0.56 GE (15), Siemens (25),
Toshiba (22), Shimadzu (8),
Philips/Hitachi (3)
CHR LE 9 0.55 0.02 0.53 0.57 Philips/Hitachi (9)
LEGP/AP LE 25 0.65 0.04 0.63 0.66 GE (10), Siemens (3), Shimadzu (7),
Philips/Hitachi (4), ADAC (1)
ELEGP (old) LE 4 0.62 0.03 0.57 0.67 GE (4)
ELEGP (new) LE 14 0.75 0.03 0.73 0.76 GE (14)
LMEGP ME 46 0.83 0.05 0.81 0.85 Siemens (25), Toshiba (21)
MEGP/GAP ME 40 0.88 0.05 0.86 0.89 GE (13), Siemens (9), Toshiba (3),
Shimadzu (8), Philips/Hitachi (7)
MELP/HEGP ME 14 0.95 0.04 0.92 0.98 Siemens (9), Toshiba (4), Hitachi (1)
LE, Low-energy; ME, medium-energy; CHR, cardiac HR; GP, general-purpose; AP, all-purpose; GAP, general-all-purpose; ELE,
extended LE; LME, low-medium energy; LP, low penetration; HEGP, high-energy general-purpose.
Figure 3. Conversion coefficients to the reference values in
LE- and ME-collimator groups. Bars denote average values,
and histogram distributions are also shown. Although a
significant difference was observed between the mean values
of LE and ME groups, an overlap was also noted.
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Figure 4. Linear regression lines of HMRs between ME- and LE- collimator types in clinical
validation studies. (A, B) show the relationship before and after standardization. (C, D) show the
range of HMR \2.8. The marks of circle, square, and triangle are HMRs from three hospitals.
Dotted lines indicate line of identity.
Table 2. Contingency table for three HMR risk groups
LE: High risk (<1.60) Low risk (1.60–2.19) Normal (‡2.20) Total
ME
A. HMRs measured with ME- vs LE-collimator types
High risk (\1.60) 10 0 0 10
Low risk (1.60–2.19) 8 2 0 10
Normal (C2.20) 0 19 13 32
Total 18 21 13 52
B. Standardized HMR converted from ME- and LE-collimator types
High risk (\1.60) 10 1 0 11
Low risk (1.60–2.19) 1 7 0 8
Normal (C2.20) 0 3 30 33
Total 11 11 30 52
A. Degree of agreement: j = 0.07, P = .21, complete agreement = 25/52 (48%). B. Degree of agreement: j = 0.83, P\ .0001,
complete agreement = 47/52 (90%).
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photon (529 keV) of 123I is only 1.4%, the effect of
down scatter is complicated and troublesome.
While various methods have been proposed to
improve the quantification of 123I tracers, including a
multiple energy window method,9,15 deconvolution of
the septal penetration method,17 and a direct empirical
conversion method,18 the calibration phantom method
has an advantage, which is demonstrated as follows.
Although the simplest approach was creating a linear
regression equation between measured HMRs with both
LE and ME collimators, the empirical method cannot be
applicable to other camera-collimator combinations or
multicenter study protocols. The second approach was
based on multi-window acquisition methods. However,
subtraction of sub-energy window usually shows low
counts, which caused errors in calculation.14 In contrast,
the phantom-based method used in this study is consid-
ered to be a simple method to understand differences in
camera and collimator systems.10 With this phantom,
because of the homogeneous and flat distribution of the
tracer, the reproducibility of HMRs was excellent when
the acquisition condition was the same. It was also
confirmed that in JSNM-working group databases, the
HMR measured with LE-type collimators and corrected
by the calibration phantom showed similar normal
distribution comparable to that from ME
collimators.10,16
In 225 experiments of 84 institutions, the similar
collimators, for example LEHR and LEGP, did not show
the same conversion coefficient, depending on the
vendors. Even in the same vendor, the ELEGP collima-
tor made from 2002 to 2004 showed significantly
different values compared with that made after 2008,
and the latter showed higher HMRs. This sort of
modification and improvement of collimator design
has been performed in companies, although the name of
collimators was the same. According to the results of
this study, the collimator types might be classified into 7
or 8 major subgroups. Hence, two types, namely LE and
ME types, are considered a rough classification at
present, and the borders of LE and ME types are
obscure.
Feasibility for converting to the standard HMR was
investigated in this study. In the multicenter study for
differentiating dementia with Lewy bodies and Alzhei-
mer disease, HMRs derived from LE collimators were
converted to institutional ME-type comparable values.10
In the study, we assumed that the differences among
various ME types were small, and combined distribution
of HMR was improved after correction. Because we
cannot use a specific collimator from one vendor as a
single standard, our proposal is to use the average
Kstandard of MEGP collimators as the standard. With this
approach, only an initial phantom experiment is required
when a new camera system is installed. Although
mathematical values might have been used as the
standard, all institutions should change their HMRs for
institutional daily practice.
The cross-calibration method can be used to apply
other published studies to one’s own institution. For
example, a published study used the LE collimator, and
the LME collimator might be used in an individual
hospital. Based on the ADMIRE-HF study showing a
threshold of 1.60 for good and poor prognosis in patients
with chronic heart failure using a LE-type collimator,12
the users of the LME collimator can assume that it is
comparable to 1.91 in their institution. If the HMR of
1.77 was used to differentiate dementia with Lewy
bodies and others using LE-type collimators,19 a thresh-
old of 1.77 can be translated to 2.16 for users of the
LME collimator. Although a number of studies using a
certain threshold of HMR are valid in the similar
acquisition conditions, we might be able to integrate
experiences of published MIBG studies using this sort of
cross-calibration.
When a prediction model is considered for predict-
ing future mortality, current large-scale databases might
be prepared using the conventional LEHR collimators.20
Recently, HMRs have been gradually increasing
because new collimators covering 123I energy have
become available in the nuclear medicine field. If an
HMR from ME-comparable conditions is directly used
for predicting mortality rate, it may underestimate the
risk for future events, and the measured HMR should be
converted to LE-comparable values.
LIMITATIONS
Even after the standardization based on the phantom
study, we found slight underestimation of HMRs in the
range of HMR [2.5, probably due to the structural
difference between the phantom and the human body.
One of the important differences in human is compli-
cated down-scatter activity from the high-energy
photons coming from outside of the filed of view, such
as liver, kidney, and bladders.
While complete correction from a physical point of
view is ideal in a whole range, the major purpose of
standardization is its use in determining a threshold for
prognosis and a lower normal range. From this consid-
eration, the most important range of HMR was around
1.6-1.7 for discriminating good and bad prognosis, and a
threshold of 2.0-2.2 between normal and abnor-
mal.2,12,13,16 In other words, the normal or higher
range has no prognostic meaning. Finally, standard
HMR used averaged values from 44 experiments with
the commonest ME types, which may be modified when
required.
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NEW KNOWLEDGE GAINED
In terms of HMR calculation, the collimator type
was classified not simply into two LE and ME types but
includes various intermediate types. Using the cross-
calibration phantom method, however, institutional
HMRs can be converted to standardized HMRs compa-
rable to the commonest ME-collimator. The cross-
calibration method works well in the range of low and
normal HMRs when classifying into main risk groups.
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APPENDIX
Participated institutions included Asahikawa City
Hospital (Asahikawa), Bell Land General Hospital
(Sakai), Chubu Medical Center Kizawa Memorial Hos-
pital (Minokamo), Chuno Kosei Hospital (Seki),
Dokkyo Medical University (Shimotsuga), Fukushima
Medical University (Fukushima), Gifu Prefectural Gen-
eral Medical Center (Gifu), Gifu University Hospital
(Gifu), Haibara General Hospital (Makinohara), Hako-
date Municipal Hospital (Hakodate), Higashiosaka City
General Hospital (Higashiosaka), Hiroshima Red Cross
Hospital & Atomic-bomb Survivors Hospital (Hiro-
shima), Iizuka Hospital (Iizuka), Ikeda Municipal
Hospital (Ikeda), Itami City Hospital (Itami), Japanese
Red Cross Asahikawa Hospital (Asahikawa), Japanese
Red Cross Ashikaga Hospital (Ashikaga), Japanese Red
Cross Gifu Hospital (Gifu), Japanese Red Cross Kitami
Hospital (Kitami), Japanese Red Cross Kyoto Daini
Hospital (Kyoto), Jichi Medical University Hospital
(Shimotsuke), Juntendo Tokyo Koto Geriatric Medical
Center (Tokyo), Juntondo University Hospital (Tokyo),
Juntondo University Nerima Hospital (Tokyo), Juntondo
University Urayasu Hospital (Urayasu), Kanagawa Pre-
fectural Ashigarakami Hospital (Ashigarakami-gun),
Kanazawa Municipal Hospital (Kanazawa), Kanazawa
University Hospital (Kanazawa), Kawasaki Hospital
(Kobe), Keio Univeristy Hospital (Tokyo), Kin-ikyo
Chuo Hospital (Sapporo), Konan Kakogawa Hospital
(Kakogawa), Kyoto Prefectural University of Medicine -
University Hospital (Kyoto), Mimihara Oimatsu Clinic
(Sakai), Murakami Memorial Hospital Asahi University
(Gifu), Nagaoka Red Cross Hospital (Nagaoka), Naga-
saki Rousai Hospital (Sasebo), Nagoya City East
Medical Center (Nagoya), National Center for Geriatrics
and Gerontology (Obu), National Center for Global
Health and Medicine (Tokyo), National Cerebral and
Cardiovascular Center (Suita), National Hospital Orga-
nization Disaster Medical Center (Tachikawa), National
Hospital Organization Kumamoto Saishunso National
Hospital (Koshi), National Hospital Organization Mi-
nami Kyoto Hospital (Joyo), National Hospital
Organization Okinawa National Hospital (Ginowan),
National Hospital Organization Tokyo National Hospi-
tal (Kiyose), National Hospital Organization Yokohama
Medical Center (Yokohama), National Kyushu Medical
Center (Fukuoka), Nippon Medical School Hospital
(Tokyo), Nishikobe Medical Center (Kobe), NTT Med-
ical Center Tokyo (Tokyo), Obihiro-Kosei General
Hospital (Obihiro), Ogaki Municipal Hospital (Ogaki),
Okayama Kyokuto Hospital (Okayama), Okayama Uni-
versity Hospital (Okayama), Osaka General Medical
Center (Osaka), Rumoi Municipal Hospital (Rumoi),
Saiseikai Kumamoto Hospital (Kumamoto), Saiseikai
Noe Hospital (Osaka), Sapporo City General Hospital
(Sapporo), Sapporo-Kosei General Hospital (Sapporo),
Seihoku Chuo Hospital (Goshogawara), Shizuoka Gen-
eral Hospital (Shizuoka), Showa General Hospital
(Kodaira), Sunagawa City Medical Center (Sunagawa),
Surugadai Nihon University Hospital (Tokyo), Suzuka
Central General Hospital (Suzuka), Tenri Hospital
(Tenri), The Cardiovascular Institute Hospital (Tokyo),
The Jikei University Hospital (Tokyo), Toho University
Omori Hospital (Tokyo), Tohoku University Hospital
(Sendai), Tokyo Medical University (Tokyo), Tokyo
Medical University Hospital (Hachioji), Tokyo Metro-
politan Geriatric Hospital and Institute of Gerontology
(Tokyo), Tokyo Women’s Medical University Hospital
(Tokyo), Toranomon Hospital (Tokyo), Tottori Univer-
sity Hospital (Yonago), Toyonaka Municipal Hospital
(Toyonaka), Tsukuba University Hospital (Tsukuba),
Yogogawa Christian Hospital (Osaka), Yokohama City
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University Hospital (Yokohama), Yokohama City Uni-
versity Medical Center (Yokohama), and Yokohama
Minami Kyousai Hospital (Yokohama).
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